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Introduction: Gender dysphoria (GD) is a condition in which there is a marked incongru-
ence between an individual’s psychological perception of his/her sex and their biological
phenotype. Gender identity disorder was officially renamed “gender dysphoria” in the
DSM-V in 2013. The prevalence and demographics of GD vary according to geographical
location and has not been well-documented in Ireland.
Methods:We retrospectively reviewed medical records of 218 patients with suspected or
confirmed GD referred to our endocrine service for consideration of hormonal therapy (HT)
between 2005 and early 2014.We documented their demographics, clinical characteristics,
and treatment during the study period.
Results:The prevalence of GD in the Irish population was 1:10,154 male-to-female (MTF)
and 1:27,668 female-to-male (FTM), similar to reported figures in Western Europe. 159 of
the patients were MTF and 59 were FTM, accounting for 72.9% and 27.1% of the cohort,
respectively. The rate of referral has increased year-on-year, with 55 patients referred in
2013 versus 6 in 2005. Mean ages were 32.6 years (MTF) and 32.2 years (FTM). 22 of
the patients were married and 41 had children, with 2 others having pregnant partners.
37.6% were referred by a psychologist, with the remainder evenly divided between GPs
and psychiatric services. There were low rates of coexistent medical illness although psy-
chiatric conditions were more prevalent, depression being a factor in 34.4% of patients.
5.9% of patients did not attend a mental health professional. 74.3% are currently on HT,
and 9.17% have had gender reassignment surgery (GRS). Regret following hormonal or
surgical treatment was in line with other Western European countries (1.83%).
Conclusion:The incidence of diagnosis and referral of GD in Ireland is increasing.This brings
with it multiple social, health, and financial implications. Clear and accessible treatment
pathways supported by mental health professionals is essential.
Keywords: gender dysphoria, gender identity disorder, transgender, gender reassignment surgery, gonadectomy,
hormone therapy
INTRODUCTION
Gender dysphoria (GD) is a recognized condition in which there is
marked incongruence between an individual’s psychological per-
ception of his/her sex and their biological phenotype (1). GD has
replaced the term gender identity disorder (GID) in the 2013 pub-
lication of the DSM-V, which itself replaced “transexualism” in
1980. The cause is not well understood and is believed to be due
to a complex interaction of psychosocial and biological factors
during development (2, 3).
Prevalence varies based on geographical location, with higher
rates in Western Europe and America (0.001–0.002%) (4–6) com-
pared to lower rates in Japan (0.0009%) (7). In most studies,
male-to-female (MTF) GD cases tend to significantly outnumber
female-to-male (FTM) cases (7).
The DSM-V has strict criteria for the diagnosis of GD that differ
between children and adults. However, both include a persistent
and strong conviction that they are the wrong sex, feel discomfort,
distress, or anxiety with their gender-role and sexual character-
istics, and possess a strong and persistent desire to be a member
of the opposite sex (1). These criteria are based on the assump-
tion that GD is a purely psychiatric condition which is a topic of
controversy.
The complex nature of GD requires that psychological, social,
and medical issues are addressed by a multidisciplinary team.
The Department of Endocrinology in St. Columcille’s Hospi-
tal (SCH), Dublin, has been managing patients with GD since
2000. Patients are referred for consideration of hormonal ther-
apy (HT) by a mental health professional or GP in the majority
of cases. We have previously reported the characteristics of the
first 52 patients referred for HT in SCH (8), however, GD in
Ireland remains poorly investigated. This paper aims to update
the characteristics of GD in Ireland, show the current prevalence
of the condition, and discuss the need for developing accessible,
well-defined pathways of care.
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MATERIALS AND METHODS
We retrospectively reviewed the medical records of 218 patients
referred to the GD clinic between 2005 and early 2014. A diag-
nosis had been made by a MHP based on DSM-IV/V criteria in
most instances, however, some patients required a referral from
the clinic to a mental health professional if this had not occurred
This initial consultation included a full medical and surgical his-
tory and examination as well as baseline laboratory investigations;
full blood count, renal, liver, and bone profiles, fasting lipids, and
glucose as well as hormonal profiling.
Data collection focused on documentation of past medical and
surgical history (including hypertension, coronary artery disease,
thromboembolic disease, dyslipidemia, diabetes mellitus, etc.),
psychiatric background (including depression and autistic spec-
trum disorder etc.), and family history (including cardiovascular
conditions etc.). Smoking and alcohol use were also recorded. GD-
specific questioning aimed to establish age at self-diagnosis, time
spent in desired role, and hormonal or surgical therapy prior to
presentation, etc (Table 1).
Consideration for HT required that patients were diagnosed by
a minimum of one, preferably two mental health professionals.
In our service, we aimed to initiate HT at the second visit,
thus this necessitated that a detailed discussion with the patient
regarding the risks and benefits of HT be undertaken at the initial
consultation. Providing there were no contraindications and the
patient received a definitive diagnosis of GD from an appropriate
mental health specialist, HT could commence on the second con-
sultation. We also analyzed the incidence of regret or adverse effects
to treatment in those presenting for follow-up. Those wishing to
proceed with gender-related surgery were referred to appropriate
specialists in Ireland or abroad.
RESULTS
DEMOGRAPHICS
In the study, 218 patients with GD were referred to our clinic
between 2005 and early 2014 (Table 1). 72.9% of these were MTF
and 27.1% FTM, with a MTF:FTM ratio of 2.7:1. Based on the 2011
census reports (9), this indicates a prevalence of GD in 1:14,756
people (0.0067% of the population), categorized into 1:10,154
MTF (0.0098%) and 1:27,668 FTM (0.0036%). Seventy-one per-
cent of the patients were Irish, with Leinster providing the most
patients when subdividing the cohort based on region. The num-
bers of patients being referred increased steadily over the 9 years
study period, from 6 referrals in 2005 to 55 in 2013 (Table 2;
Figure 1).
The average age at referral was similar between both gender
groups at 32.6 years for MTF and 32.2 years for FTM, ranging
from 15 to 69 years. There was a clear trend in the study showing
people are being referred at younger ages as time goes on. The
average age at referral from 2005 to 2009 inclusive was 36.77 years,
compared with the average age between 2010 and 2013, which was
30.14 years. Twenty-one percent of the patients were married at
presentation or in the past, and 18.8% reported having children.
Two patients reported having pregnant partners, one of whom
conceived using banked sperm.
One hundred thirty-five patients (61.9%) declared their age
at self-diagnosis of GD as being pre-pubertal, with 14.7% stating
Table 1 | Demographics and co-morbidities.
Variable MTF FTM
Number 159 59
Age (years) (SD) 32.5(13.26) 32.2(11.40)
Married (previous or current) 41 5
Number with children 37 3
Prior hormone therapy 36 6
Living in role 66 44
MEDICAL HISTORY
Hypertension 17 3
Dyslipidemia 42 5
Diabetes 1 2
Cigarettes 40 17
PSYCHIATRIC CO-MORBIDITY
Depression 55 19
Schizophrenia 8 −
Bipolar affective disorder 2 2
Deliberate self-harm/suicide attempt 13 6
SD, standard deviation; MTF, male-to-female; FTM, female-to-male.
Table 2 | Number of referrals per year.
Year of referral MTF FTM Total
2005 6 − 6
2006 9 2 11
2007 7 2 9
2008 10 2 12
2009 16 5 21
2010 15 6 21
2011 25 5 30
2012 30 17 47
2013 37 18 55
2014 (to March) 3 1 4
MTF, male-to-female; FTM, female-to-male.
they realized their issues around gender as adolescents. 50.9% of
patients were living in their desired gender-role on a full-time
basis, with approximately one quarter of patients not living in role
prior to initial presentation.
The majority of referrals were made by a psychologist (37.6%),
with the remainder evenly divided between psychiatrists and GPs.
Although most patients were seen by at least one MHP, 5.96%
of patients did not attend either a psychiatrist or psychologist.
Of these, five patients received HT without prior MHP consul-
tation, however, one patient obtained the medications via the
internet and three others were on HT and also had gender-
related surgery prior to presentation. Forty-four patients (20.2%)
were on HT prior to initial visit to the GD clinic, 9 of whom
ordered it via the internet, 16 individuals sourced hormones
from practitioners either in Ireland or the UK, 9 sourced it
from overseas, and in the case of the remainder the source was
unknown.
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FIGURE 1 | Number of referrals per year.
MEDICAL AND PSYCHIATRIC CO-MORBIDITIES
Several patients had co-existing medical co-morbidities, with
dyslipidemia (21.6%), asthma (11.45%), and hypertension
(9.17%) being the most prevalent. Twenty-six percent of the
patients reported being smokers at the time of presentation, with
23.85% having smoked regularly in the past. Twelve patients con-
sumed more than 15 units of alcohol per week, however, eight
patients (3.67%) reported abusing alcohol to a damaging degree
in the past. Seventy-five (34.4%) patients had a history of depres-
sion, 25.3% of those admitting to acts of deliberate self-harm.
Other psychiatric conditions encountered included schizophre-
nia (3.67%), bipolar disorder (2.29%), and Asperger’s syndrome
(2.29%) (Table 1).
Blood samples were taken as they are important to both assess
initial risk and evaluate possible future adverse events, includ-
ing cardiovascular disease (10). Twenty-five percent were found
to have an initial fasting cholesterol of >5.3 mmol/L and 31%
had a fasting LDL of >2.6 mmol/L, both of these figures being
the upper reference range for the laboratory in SCH. Of these,
47 were known to have dyslipidemia (42 MTF versus 5 FTM), 12
people went on to commence lipid-lowering therapy, with others
initiating diet control or having a repeat sample within normal
ranges. Five people were found to have a fasting blood glucose of
>5.9 mmol/L, however, none were found to have diabetes mellitus
on repeat testing (Table 1). Nearly 20% of patients had a family
history of vascular disease including myocardial infarction (9%),
deep venous thrombosis (2%), and cerebrovascular disease (9%).
POST PRESENTATION
To date, 55 patients (22.3%) have undergone surgery, 36 (65.5%)
of these have been MTF patients. Mammoplasty was the most
common procedure, with 19 (52.8%) of those undergoing surgery
electing to have breast augmentation. Twenty (36.4%) surgical
patients opted for gender reassignment surgery (GRS), which
Table 3 | Surgical procedures in gender dysphoria patients.
Variable MTF FTM
GRS 15 9
Breast surgery 16 19
Facial surgery 6 −
Laryngeal surgery 2 −
GRS, gender reassignment surgery.
constitutes 9.17% of the total cohort. A very small number also had
facial or laryngeal surgery for voice alteration (Table 3). As there
are currently no GRS services in Ireland, patients are referred to
a variety of centers in the United Kingdom and elsewhere. Addi-
tionally, there are currently 11 patients referred to Charing Cross
Hospital for consideration of GRS.
Dual energy X-ray absorptiometry (DEXA) scanning is now
part of the standard screening protocol of patients presenting to
our clinic. In our cohort, 39 patients (17.9%) underwent this inves-
tigation at time of last known follow-up, with 20.5% of those
studied discovered to have osteopenia, and 7.7% diagnosed with
osteoporosis.
Thirty-seven patients (17%) reported adverse effects following
hormonal or surgical therapy. Eight patients reported decreased
mood or libido, six patients were found to have developed dys-
lipidemia, five patients had hot flushes/headaches, and one patient
developed a fistula post GRS. Four patients (1.8%) expressed regret
following treatment. All of the incidences of regret involved MTF,
three of who were post GRS with the other in the hormonal phase
of treatment.
DISCUSSION
In this retrospective study, we characterized GD patients attending
an endocrine unit in the Republic of Ireland. From this study, the
prevalence of GD is 1:10,154 MTF (0.0098%) and 1:27,668 FTM
(0.0036%). This is comparable to the prevalence of GD reported in
Western Europe, which ranges from 1:11,900 to 1:18,000 for MTF
and 1:30,400 to 1:54,000 for FTM (4, 10–12). Our analysis echoed
similar international studies in that we collated data from a single
specialist GD clinic. De Cuypere et al. reviewed 10 such studies
spanning 39 years with prevalence very much matching our own
(10). The prevalence rate of GD in our cohort is likely to reflect
that of the Republic of Ireland as a nation, as our unit has been the
main specialist center in the country over the study period.
In the seventh version of the World Professional Association for
Transgender Health (WPATH) Standards of Care for the Health
of Transsexual, Transgender, and Gender-Non-conforming People
(13), it is highlighted that in more recent analyses there appears to
be a higher prevalence of GD, possibly reflecting an increase in the
number of people seeking help from healthcare professionals (13–
15). This hypothesis is supported by our analysis, which shows 6
referrals to our service in 2005 versus 55 in 2013.
Our MTF/FTM sex ratio of 2.7:1 is similar to the ratio of 3:1
reported in our previous study (8) and the sex ratio reported in
Western Europe (10, 11). It is in line international data ranging
from 3 to 5:1 (16).
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The age of initial assessment was the same for both MTF
and FTM (32 years). This is significantly different to our previ-
ous figures which indicated FTM patients presented, on average,
8 years younger than MTF (8). Age of presentation for MTF
has decreased dramatically (39 versus 32.6) while that of FTM
patients has remained approximately the same (31 versus 32.2)
(8). The reason for this is unclear but may represent the condition
now being more socially acceptable facilitating earlier presenta-
tion. This age is in line with a Belgian study, which showed a
mean age of initial presentation of ~30 years (10). Over 60% of
patients declared their age at self-diagnosis to be pre-pubertal
which highlights the need for early recognition and diagnosis of
the condition.
21% of the patients were married at presentation or in the
past, and 18.8% reported having children. This is lower than the
reported rates in similar European studies (10). Two of the patients
had pregnant partners, one of whom conceived using banked
sperm.
The rate of co-existing medical illness such as hypertension
and diabetes were low in GD patients, which could perhaps be
expected as the patients are generally young (average age 32 years).
It is important to identify and optimize control of these medical
co-morbidities prior to initiating the hormonal phase of treat-
ment, as they can be exacerbated by hormones such as estrogen
(17–19). Close attention should be paid to the possibility of car-
diovascular events, as accruing evidence has suggested that MTF
GD patients may be at an increased cardiovascular risk (20–22).
Twenty-six percent of patients were smokers at initial presen-
tation which is in line with the national average of 29% (23).
Patients were informed that they would not be commenced on
HT until they had ceased smoking due to the increased risk of
venous thrombosis (24).
Depression was common to 34.4% of patients, while the inci-
dence of other major psychiatric illnesses was relatively low. A
survey of Dutch psychiatrists regarding psychiatric co-morbidity
in those with GD found that 61% of their cohort had a co-existing
psychiatric disorder (25). The presence of such a high rate of co-
morbid psychiatric illness underlines the need for a well-defined
and rigidly adhered-to mental health consultation service. While
our rate of patients who did not attend a MHP (5.96%) is low, it
outlines the challenges faced by specialist centers in ensuring that
patients with GD receive the appropriate mental health support in
the setting of increased referrals.
Currently, there are no centers in Ireland which provide GRS,
which may have contributed to only 11% of our patients under-
going sex reassignment surgery. However, it is worth noting that
there is an agreement between the Irish Health Service Executive
and certain GRS centers in other countries to facilitate ease of
access for Irish patients wishing to undergo GRS. Unfortunately,
this system is somewhat convoluted and frequently causes delays
in access to surgery. This is a frustration experienced by many of
the patients examined in our study.
The regret rate following both HT and GRS was low with four
(2%) patients expressing regret (all MTF). This is slightly higher
than previously reported figures of 1–1.5% for MTF (26, 27).
Three of these had gender-related surgery and one had received
hormones as the only treatment. Although low, the regret rate of
2% illustrates the need for continued input from mental health
professionals beyond GRS. Unfortunately, these services are not
always readily available, and this is a matter for further discussion.
CONCLUSION
The prevalence of GD in the Republic of Ireland is comparable
to that reported in Western Europe. However, the true prevalence
may be difficult to assess due to patient worries regarding stigma
and societal acceptance of the condition. The number of patients
treated by our unit is increasing each year, which will pose consid-
erable challenges with already limited resources. The liaison with
mental health services is of critical importance to patients and to
the success of treatment. Difficulties in obtaining ongoing mental
health care are all too common and lead to the burden of care rest-
ing on the endocrinology service. It is vital that a well-defined and
accessible treatment pathway is continually developed in order to
ensure a gold standard of care for patients with GD.
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